HomeCDXC • NASDAQ
add
Chromadex Corp
Previous close
$3.44
Day range
$3.41 - $3.53
Year range
$1.25 - $4.65
Market cap
265.77M USD
Avg Volume
282.92K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 22.74M | 11.89% |
Operating expense | 13.95M | -4.93% |
Net income | -15.00K | 99.32% |
Net profit margin | -0.07 | 99.35% |
Earnings per share | 0.00 | 100.00% |
EBITDA | -49.00K | 97.60% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 27.73M | 5.63% |
Total assets | 54.04M | 1.62% |
Total liabilities | 23.32M | -10.39% |
Total equity | 30.72M | — |
Shares outstanding | 76.10M | — |
Price to book | 8.39 | — |
Return on assets | -1.18% | — |
Return on capital | -1.94% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -15.00K | 99.32% |
Cash from operations | -264.00K | -108.05% |
Cash from investing | -12.00K | -140.00% |
Cash from financing | 596.00K | 6,060.00% |
Net change in cash | 320.00K | -90.20% |
Free cash flow | -332.00K | -107.68% |
About
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.
In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure. ChromaDex no longer sells pTeroPure. Wikipedia
Founded
1999
Headquarters
Website
Employees
106
